The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Circulating Tumor Cell Diagnostics Market Research Report 2025
Synopsis
Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
The global Circulating Tumor Cell Diagnostics market was valued at US$ 4840.3 million in 2023 and is anticipated to reach US$ 9239.7 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cell Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cell Diagnostics.
Report Scope
The Circulating Tumor Cell Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Circulating Tumor Cell Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cell Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Segment by Type
CTC Enrichment
CTC Detection
CTC Analysis
Segment by Application
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cell Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
The global Circulating Tumor Cell Diagnostics market was valued at US$ 4840.3 million in 2023 and is anticipated to reach US$ 9239.7 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cell Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cell Diagnostics.
Report Scope
The Circulating Tumor Cell Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Circulating Tumor Cell Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cell Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Segment by Type
CTC Enrichment
CTC Detection
CTC Analysis
Segment by Application
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cell Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CTC Enrichment
1.2.3 CTC Detection
1.2.4 CTC Analysis
1.3 Market by Application
1.3.1 Global Circulating Tumor Cell Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Tumorigenesis research
1.3.3 EMT biomarkers development
1.3.4 Cancer stem cell research
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cell Diagnostics Market Perspective (2019-2030)
2.2 Circulating Tumor Cell Diagnostics Growth Trends by Region
2.2.1 Global Circulating Tumor Cell Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Circulating Tumor Cell Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Circulating Tumor Cell Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Circulating Tumor Cell Diagnostics Market Dynamics
2.3.1 Circulating Tumor Cell Diagnostics Industry Trends
2.3.2 Circulating Tumor Cell Diagnostics Market Drivers
2.3.3 Circulating Tumor Cell Diagnostics Market Challenges
2.3.4 Circulating Tumor Cell Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cell Diagnostics Players by Revenue
3.1.1 Global Top Circulating Tumor Cell Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Circulating Tumor Cell Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Circulating Tumor Cell Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor Cell Diagnostics Revenue
3.4 Global Circulating Tumor Cell Diagnostics Market Concentration Ratio
3.4.1 Global Circulating Tumor Cell Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cell Diagnostics Revenue in 2023
3.5 Circulating Tumor Cell Diagnostics Key Players Head office and Area Served
3.6 Key Players Circulating Tumor Cell Diagnostics Product Solution and Service
3.7 Date of Enter into Circulating Tumor Cell Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cell Diagnostics Breakdown Data by Type
4.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2025-2030)
5 Circulating Tumor Cell Diagnostics Breakdown Data by Application
5.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Circulating Tumor Cell Diagnostics Market Size (2019-2030)
6.2 North America Circulating Tumor Cell Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024)
6.4 North America Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor Cell Diagnostics Market Size (2019-2030)
7.2 Europe Circulating Tumor Cell Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024)
7.4 Europe Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Circulating Tumor Cell Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor Cell Diagnostics Market Size (2019-2030)
9.2 Latin America Circulating Tumor Cell Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Circulating Tumor Cell Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Janssen Diagnostics
11.1.1 Janssen Diagnostics Company Detail
11.1.2 Janssen Diagnostics Business Overview
11.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Introduction
11.1.4 Janssen Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.1.5 Janssen Diagnostics Recent Development
11.2 Advanced Cell Diagnostics
11.2.1 Advanced Cell Diagnostics Company Detail
11.2.2 Advanced Cell Diagnostics Business Overview
11.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Introduction
11.2.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.2.5 Advanced Cell Diagnostics Recent Development
11.3 Aviva Biosciences
11.3.1 Aviva Biosciences Company Detail
11.3.2 Aviva Biosciences Business Overview
11.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Introduction
11.3.4 Aviva Biosciences Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.3.5 Aviva Biosciences Recent Development
11.4 Biocept Inc
11.4.1 Biocept Inc Company Detail
11.4.2 Biocept Inc Business Overview
11.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Introduction
11.4.4 Biocept Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.4.5 Biocept Inc Recent Development
11.5 Biofluidica Inc.
11.5.1 Biofluidica Inc. Company Detail
11.5.2 Biofluidica Inc. Business Overview
11.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Introduction
11.5.4 Biofluidica Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.5.5 Biofluidica Inc. Recent Development
11.6 CellTraffix Inc.
11.6.1 CellTraffix Inc. Company Detail
11.6.2 CellTraffix Inc. Business Overview
11.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Introduction
11.6.4 CellTraffix Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.6.5 CellTraffix Inc. Recent Development
11.7 Clearbridge BioMedics Pte Ltd
11.7.1 Clearbridge BioMedics Pte Ltd Company Detail
11.7.2 Clearbridge BioMedics Pte Ltd Business Overview
11.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Introduction
11.7.4 Clearbridge BioMedics Pte Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.7.5 Clearbridge BioMedics Pte Ltd Recent Development
11.8 Epic Sciences Inc.
11.8.1 Epic Sciences Inc. Company Detail
11.8.2 Epic Sciences Inc. Business Overview
11.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Introduction
11.8.4 Epic Sciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.8.5 Epic Sciences Inc. Recent Development
11.9 Fluxion Biosciences Inc.
11.9.1 Fluxion Biosciences Inc. Company Detail
11.9.2 Fluxion Biosciences Inc. Business Overview
11.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Introduction
11.9.4 Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.9.5 Fluxion Biosciences Inc. Recent Development
11.10 ScreenCell
11.10.1 ScreenCell Company Detail
11.10.2 ScreenCell Business Overview
11.10.3 ScreenCell Circulating Tumor Cell Diagnostics Introduction
11.10.4 ScreenCell Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.10.5 ScreenCell Recent Development
11.11 Silicon Biosystems
11.11.1 Silicon Biosystems Company Detail
11.11.2 Silicon Biosystems Business Overview
11.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Introduction
11.11.4 Silicon Biosystems Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.11.5 Silicon Biosystems Recent Development
11.12 Sysmex Corporation
11.12.1 Sysmex Corporation Company Detail
11.12.2 Sysmex Corporation Business Overview
11.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Introduction
11.12.4 Sysmex Corporation Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.12.5 Sysmex Corporation Recent Development
11.13 Greiner Bio-One GmbH
11.13.1 Greiner Bio-One GmbH Company Detail
11.13.2 Greiner Bio-One GmbH Business Overview
11.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Introduction
11.13.4 Greiner Bio-One GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.13.5 Greiner Bio-One GmbH Recent Development
11.14 AdnaGen AG
11.14.1 AdnaGen AG Company Detail
11.14.2 AdnaGen AG Business Overview
11.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Introduction
11.14.4 AdnaGen AG Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.14.5 AdnaGen AG Recent Development
11.15 Apocell Inc
11.15.1 Apocell Inc Company Detail
11.15.2 Apocell Inc Business Overview
11.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Introduction
11.15.4 Apocell Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.15.5 Apocell Inc Recent Development
11.16 Biocep Ltd
11.16.1 Biocep Ltd Company Detail
11.16.2 Biocep Ltd Business Overview
11.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Introduction
11.16.4 Biocep Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.16.5 Biocep Ltd Recent Development
11.17 Canopus Bioscience Ltd
11.17.1 Canopus Bioscience Ltd Company Detail
11.17.2 Canopus Bioscience Ltd Business Overview
11.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Introduction
11.17.4 Canopus Bioscience Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.17.5 Canopus Bioscience Ltd Recent Development
11.18 Creatv Microtech Inc
11.18.1 Creatv Microtech Inc Company Detail
11.18.2 Creatv Microtech Inc Business Overview
11.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Introduction
11.18.4 Creatv Microtech Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.18.5 Creatv Microtech Inc Recent Development
11.19 Ikonisys Inc
11.19.1 Ikonisys Inc Company Detail
11.19.2 Ikonisys Inc Business Overview
11.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Introduction
11.19.4 Ikonisys Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.19.5 Ikonisys Inc Recent Development
11.20 IV Diagnostics Inc
11.20.1 IV Diagnostics Inc Company Detail
11.20.2 IV Diagnostics Inc Business Overview
11.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Introduction
11.20.4 IV Diagnostics Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.20.5 IV Diagnostics Inc Recent Development
11.21 Miltenyi Biotech GmbH
11.21.1 Miltenyi Biotech GmbH Company Detail
11.21.2 Miltenyi Biotech GmbH Business Overview
11.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Introduction
11.21.4 Miltenyi Biotech GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.21.5 Miltenyi Biotech GmbH Recent Development
11.22 Nanostring Technologies Inc
11.22.1 Nanostring Technologies Inc Company Detail
11.22.2 Nanostring Technologies Inc Business Overview
11.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Introduction
11.22.4 Nanostring Technologies Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.22.5 Nanostring Technologies Inc Recent Development
11.23 Rarecells Diagnostics.
11.23.1 Rarecells Diagnostics. Company Detail
11.23.2 Rarecells Diagnostics. Business Overview
11.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Introduction
11.23.4 Rarecells Diagnostics. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.23.5 Rarecells Diagnostics. Recent Development
11.24 Vitatex Inc
11.24.1 Vitatex Inc Company Detail
11.24.2 Vitatex Inc Business Overview
11.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Introduction
11.24.4 Vitatex Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.24.5 Vitatex Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of CTC Enrichment
Table 3. Key Players of CTC Detection
Table 4. Key Players of CTC Analysis
Table 5. Global Circulating Tumor Cell Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Circulating Tumor Cell Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Circulating Tumor Cell Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Circulating Tumor Cell Diagnostics Market Share by Region (2019-2024)
Table 9. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Circulating Tumor Cell Diagnostics Market Share by Region (2025-2030)
Table 11. Circulating Tumor Cell Diagnostics Market Trends
Table 12. Circulating Tumor Cell Diagnostics Market Drivers
Table 13. Circulating Tumor Cell Diagnostics Market Challenges
Table 14. Circulating Tumor Cell Diagnostics Market Restraints
Table 15. Global Circulating Tumor Cell Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Circulating Tumor Cell Diagnostics Market Share by Players (2019-2024)
Table 17. Global Top Circulating Tumor Cell Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2023)
Table 18. Ranking of Global Top Circulating Tumor Cell Diagnostics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Circulating Tumor Cell Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Circulating Tumor Cell Diagnostics Product Solution and Service
Table 22. Date of Enter into Circulating Tumor Cell Diagnostics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Circulating Tumor Cell Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2019-2024)
Table 26. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2025-2030)
Table 28. Global Circulating Tumor Cell Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2019-2024)
Table 30. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Application (2025-2030)
Table 32. North America Circulating Tumor Cell Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Circulating Tumor Cell Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Circulating Tumor Cell Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Janssen Diagnostics Company Detail
Table 48. Janssen Diagnostics Business Overview
Table 49. Janssen Diagnostics Circulating Tumor Cell Diagnostics Product
Table 50. Janssen Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 51. Janssen Diagnostics Recent Development
Table 52. Advanced Cell Diagnostics Company Detail
Table 53. Advanced Cell Diagnostics Business Overview
Table 54. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product
Table 55. Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 56. Advanced Cell Diagnostics Recent Development
Table 57. Aviva Biosciences Company Detail
Table 58. Aviva Biosciences Business Overview
Table 59. Aviva Biosciences Circulating Tumor Cell Diagnostics Product
Table 60. Aviva Biosciences Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 61. Aviva Biosciences Recent Development
Table 62. Biocept Inc Company Detail
Table 63. Biocept Inc Business Overview
Table 64. Biocept Inc Circulating Tumor Cell Diagnostics Product
Table 65. Biocept Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 66. Biocept Inc Recent Development
Table 67. Biofluidica Inc. Company Detail
Table 68. Biofluidica Inc. Business Overview
Table 69. Biofluidica Inc. Circulating Tumor Cell Diagnostics Product
Table 70. Biofluidica Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 71. Biofluidica Inc. Recent Development
Table 72. CellTraffix Inc. Company Detail
Table 73. CellTraffix Inc. Business Overview
Table 74. CellTraffix Inc. Circulating Tumor Cell Diagnostics Product
Table 75. CellTraffix Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 76. CellTraffix Inc. Recent Development
Table 77. Clearbridge BioMedics Pte Ltd Company Detail
Table 78. Clearbridge BioMedics Pte Ltd Business Overview
Table 79. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product
Table 80. Clearbridge BioMedics Pte Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 81. Clearbridge BioMedics Pte Ltd Recent Development
Table 82. Epic Sciences Inc. Company Detail
Table 83. Epic Sciences Inc. Business Overview
Table 84. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product
Table 85. Epic Sciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 86. Epic Sciences Inc. Recent Development
Table 87. Fluxion Biosciences Inc. Company Detail
Table 88. Fluxion Biosciences Inc. Business Overview
Table 89. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product
Table 90. Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 91. Fluxion Biosciences Inc. Recent Development
Table 92. ScreenCell Company Detail
Table 93. ScreenCell Business Overview
Table 94. ScreenCell Circulating Tumor Cell Diagnostics Product
Table 95. ScreenCell Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 96. ScreenCell Recent Development
Table 97. Silicon Biosystems Company Detail
Table 98. Silicon Biosystems Business Overview
Table 99. Silicon Biosystems Circulating Tumor Cell Diagnostics Product
Table 100. Silicon Biosystems Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 101. Silicon Biosystems Recent Development
Table 102. Sysmex Corporation Company Detail
Table 103. Sysmex Corporation Business Overview
Table 104. Sysmex Corporation Circulating Tumor Cell Diagnostics Product
Table 105. Sysmex Corporation Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 106. Sysmex Corporation Recent Development
Table 107. Greiner Bio-One GmbH Company Detail
Table 108. Greiner Bio-One GmbH Business Overview
Table 109. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product
Table 110. Greiner Bio-One GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 111. Greiner Bio-One GmbH Recent Development
Table 112. AdnaGen AG Company Detail
Table 113. AdnaGen AG Business Overview
Table 114. AdnaGen AG Circulating Tumor Cell Diagnostics Product
Table 115. AdnaGen AG Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 116. AdnaGen AG Recent Development
Table 117. Apocell Inc Company Detail
Table 118. Apocell Inc Business Overview
Table 119. Apocell Inc Circulating Tumor Cell Diagnostics Product
Table 120. Apocell Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 121. Apocell Inc Recent Development
Table 122. Biocep Ltd Company Detail
Table 123. Biocep Ltd Business Overview
Table 124. Biocep Ltd Circulating Tumor Cell Diagnostics Product
Table 125. Biocep Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 126. Biocep Ltd Recent Development
Table 127. Canopus Bioscience Ltd Company Detail
Table 128. Canopus Bioscience Ltd Business Overview
Table 129. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product
Table 130. Canopus Bioscience Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 131. Canopus Bioscience Ltd Recent Development
Table 132. Creatv Microtech Inc Company Detail
Table 133. Creatv Microtech Inc Business Overview
Table 134. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product
Table 135. Creatv Microtech Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 136. Creatv Microtech Inc Recent Development
Table 137. Ikonisys Inc Company Detail
Table 138. Ikonisys Inc Business Overview
Table 139. Ikonisys Inc Circulating Tumor Cell Diagnostics Product
Table 140. Ikonisys Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 141. Ikonisys Inc Recent Development
Table 142. IV Diagnostics Inc Company Detail
Table 143. IV Diagnostics Inc Business Overview
Table 144. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product
Table 145. IV Diagnostics Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 146. IV Diagnostics Inc Recent Development
Table 147. Miltenyi Biotech GmbH Company Detail
Table 148. Miltenyi Biotech GmbH Business Overview
Table 149. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product
Table 150. Miltenyi Biotech GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 151. Miltenyi Biotech GmbH Recent Development
Table 152. Nanostring Technologies Inc Company Detail
Table 153. Nanostring Technologies Inc Business Overview
Table 154. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product
Table 155. Nanostring Technologies Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 156. Nanostring Technologies Inc Recent Development
Table 157. Rarecells Diagnostics. Company Detail
Table 158. Rarecells Diagnostics. Business Overview
Table 159. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product
Table 160. Rarecells Diagnostics. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 161. Rarecells Diagnostics. Recent Development
Table 162. Vitatex Inc Company Detail
Table 163. Vitatex Inc Business Overview
Table 164. Vitatex Inc Circulating Tumor Cell Diagnostics Product
Table 165. Vitatex Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024) & (US$ Million)
Table 166. Vitatex Inc Recent Development
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Circulating Tumor Cell Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Circulating Tumor Cell Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. CTC Enrichment Features
Figure 4. CTC Detection Features
Figure 5. CTC Analysis Features
Figure 6. Global Circulating Tumor Cell Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Circulating Tumor Cell Diagnostics Market Share by Application: 2023 VS 2030
Figure 8. Tumorigenesis research Case Studies
Figure 9. EMT biomarkers development Case Studies
Figure 10. Cancer stem cell research Case Studies
Figure 11. Others Case Studies
Figure 12. Circulating Tumor Cell Diagnostics Report Years Considered
Figure 13. Global Circulating Tumor Cell Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Circulating Tumor Cell Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Circulating Tumor Cell Diagnostics Market Share by Region: 2023 VS 2030
Figure 16. Global Circulating Tumor Cell Diagnostics Market Share by Players in 2023
Figure 17. Global Top Circulating Tumor Cell Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Circulating Tumor Cell Diagnostics Revenue in 2023
Figure 19. North America Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Circulating Tumor Cell Diagnostics Market Share by Country (2019-2030)
Figure 21. United States Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Circulating Tumor Cell Diagnostics Market Share by Country (2019-2030)
Figure 25. Germany Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Circulating Tumor Cell Diagnostics Market Share by Region (2019-2030)
Figure 33. China Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Circulating Tumor Cell Diagnostics Market Share by Country (2019-2030)
Figure 41. Mexico Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Circulating Tumor Cell Diagnostics Market Share by Country (2019-2030)
Figure 45. Turkey Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Janssen Diagnostics Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 48. Advanced Cell Diagnostics Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 49. Aviva Biosciences Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 50. Biocept Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 51. Biofluidica Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 52. CellTraffix Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 53. Clearbridge BioMedics Pte Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 54. Epic Sciences Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 55. Fluxion Biosciences Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 56. ScreenCell Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 57. Silicon Biosystems Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 58. Sysmex Corporation Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 59. Greiner Bio-One GmbH Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 60. AdnaGen AG Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 61. Apocell Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 62. Biocep Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 63. Canopus Bioscience Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 64. Creatv Microtech Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 65. Ikonisys Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 66. IV Diagnostics Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 67. Miltenyi Biotech GmbH Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 68. Nanostring Technologies Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 69. Rarecells Diagnostics. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 70. Vitatex Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2019-2024)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
